USP22 and breast cancer: Moreover, our findings demonstrate that USP22 epigenetically mediates the OXPHOS-dependent CSC- and drug-tolerant features, thereby, unveiling the potential therapeutic value of this DUB to combat the metabolic vulnerabilities of these particularly aggressive BC subtypes.